The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease
Open accessAbstract
Background: There is currently a lack of reliable and easily accessible biomarkers predicting cognitive decline in Alzheimer’s disease (AD). Synaptic dysfunction and loss occur early in AD and synaptic loss measured in the brain tissue and by PET are closely linked to cognitive decline, rendering synaptic proteins a promising target for biomarker development. Methods: We used novel Simoa assays to measure cerebrospinal fluid (CSF) levels of two synaptic biomarker candidates, postsynaptic density protein 95 (PSD-95/DLG4), and the presynaptically localized synaptosomal-associated protein 25 (SNAP-25), as well as neurogranin (Ng), an established postsynaptic biomarker. CSF samples from two well-characterized cohorts ( n =178 and n =156) were selected from banked samples obtained from diagnostic lumbar punctures containing subjects with amyloid-ß (Aß) positive AD, subjects with non-AD neurodegenerative diseases, subjects with other neurological conditions, and healthy controls (HC). Results: All subjects had detectable CSF levels of PSD-95, SNAP-25, and Ng. CSF levels of PSD-95, SNAP-25, and Ng were all correlated, with the strongest correlation between the presynaptic SNAP-25 and the postsynaptic neurogranin. AD subjects had on average higher concentrations of all three synaptic markers compared to those with non-AD neurodegenerative diseases, other neurological disorders, and HCs. Increased CSF levels of PSD-95, SNAP-25, and Ng were, however, not specific for AD and were present in sporadic cases with inflammatory or vascular disorders as well. High CSF levels of PSD-95 were also observed in a few subjects with other neurodegenerative disorders. Conclusion: The data establishes PSD-95 as a promising CSF marker for neurodegenerative disease synaptic pathology, while SNAP-25 and Ng appear to be somewhat more specific for AD. Together, these synaptic markers hold promise to identify early AD pathology, to correlate with cognitive decline, and to monitor responses to disease-modifying drugs reducing synaptic degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, the AD-specific increase of CSF SNAP25 and Ng compared with bvFTD that we reported, corroborates previous findings [44,45].”
From The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the above concern, even though classical biomarkers such as Aβ42, Tau, and PTau are accepted clinical diagnostic hallmarks of AD, they are not predictive of cognitive decline [9].”
From Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of particular note is the evidence that no synaptic proteins were not associated with CSF NfL in any clinical group, concurrent with data from other recent cohorts [1, 9, 29].”
From Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diversity of synaptic pathology across several neurodegenerative dementia is further reflected by the fact that strong associations can be found between some synaptic proteins but not all, as well as the reported lack of correlation of synaptic biomarkers with CSF neurofilament light (NfL) levels [1, 9–11].”
In the citing paper
“These results are in line with a previous observation that synaptic proteins in the brain are differently involved in pathological disease states [9].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697 · cited 1×
“To assess the classification utility of the biomarkers, area under the curve (AUC) values were computed using a logistic regression model fit to subsets of the dataset proved significant by the previous procedures [17].”
MethodAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
A High-Confidence Human Plasma Proteome Reference Set with Estimated Concentrations in PeptideAtlas
Farrah, T., Deutsch, E. W., Omenn, G. S., Campbell, D. S., Sun, Z., Bletz, J. A., Mallick, P., Katz, J. E., Malmström, J., Ossola, R., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.006353 · Cited by 451 · cited 1×
“Ng can be detected in the plasma, but levels do not correlate with CSF levels [28, 29] possibly due to peripheral expression of Ng [30].”
BackgroundPSD95: A synaptic protein implicated in schizophrenia or autism?
Coley, A. A., & Gao, W.-J. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.016 · Cited by 359 · cited 1×
“Altered PSD-95 expression modulates receptor retention at the synapse and PSD-95 is an important factor in synaptic plasticity and the stabilization of synaptic changes during long-term potentiation [8].”
BackgroundPalmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353 · cited 1×
“Ng can be detected in the plasma, but levels do not correlate with CSF levels [28, 29] possibly due to peripheral expression of Ng [30].”
BackgroundThe clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328 · cited 1×
“Synaptic loss measured by various methods such as electron microscopy, neurochemical measurements of synaptic protein concentrations, and PET, has been reported to better correlate with cognitive decline in AD in multiple studies [4, 5], rendering synaptic proteins a promising target for biomarker development.”
MethodChen, X., Levy, J. M., Hou, A., Winters, C., Azzam, R., Sousa, A. A., Leapman, R. D., Nicoll, R. A., & Reese, T. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517045112 · Cited by 310 · cited 1×
“PSD-95 (also known as SAP-90 or DLG4) is a scaffolding protein located at the postsynaptic density of excitatory synapses which binds directly or indirectly to NMDA and AMPA receptors, potassium channels, and associated signaling proteins resulting in their clustering during the formation and maintenance of dendritic…”
BackgroundBrinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293 · cited 1×
“CSF levels of SNAP-25 have previously been shown to be elevated in AD subjects using mass spectrometry [13] or a microparticle-based immunoassay on the Singulex Erenna system [14–16].”
Method
Cited by
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79
Shanks, H. R. C., Chen, K., Reiman, E. M., Blennow, K., Cummings, J. L., Massa, S. M., Longo, F. M., Börjesson‐Hanson, A., Windisch, M., & Schmitz, T. W. (2024) · Nature Medicine · doi:10.1038/s41591-024-02977-w · Cited by 74
Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics
Dhauria, M., Mondal, R., Deb, S., Shome, G., Chowdhury, D., Sarkar, S., & Benito‐León, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010911 · Cited by 68
“Studies have demonstrated an increasing trend in CSF SNAP-25 levels in the AD population, while a decreasing index in the cerebral cortex indicates the extent of synaptic dysfunction [68].”
BackgroundWeiner, M. W., Harvey, D. J., Landau, S. M., Veitch, D. P., Neylan, T. C., Grafman, J. H., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Tosun, D., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12712 · Cited by 54
“38 Indeed, co-pathologies such as α -synuclein and TAR DNA-binding protein 43 are commonly found to accompany A β and tau at autopsy in patients withclinicallydiagnosedprobableADandMCI.”
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 57
“CSF levels of several synaptic proteins have shown elevations in AD patients compared to controls [332, 333] and/or non-AD neurodegenerative disorders [333–338].”
Metadata
- Authors
- Kivisäkk, P., Carlyle, B. C., Sweeney, T., Quinn, J. P., Ramirez, C. E., Trombetta, B. A., Mendes, M., Brock, M., Rubel, C., Czerkowicz, J., Graham, D., & Arnold, S. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Quanterix (United States) (US)
- Biogen (United States) (US)
- Corresponding author
- Kivisäkk, Pia
- ORCID
- Venue
- Alzheimer's Research & Therapy
- Published
- 2022-04-23
- Volume
- 14
- Issue
- 1
- Pages
- 58-58
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC9034610
- OpenAlex
- W4226497637
- Cited by
- 98
- References
- 32
- Citations by year
- 2026: 17 · 2025: 32 · 2024: 35 · 2023: 12 · 2022: 2
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (RF1AG059856, P30AG062421)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, synaptic proteins, PSD-95, SNAP-25, neurogranin, Simoa assay, synaptic dysfunction, cognitive decline, amyloid-beta, neurodegenerative diseases, presynaptic markers
- MeSH terms
- Disks Large Homolog 4 Protein, Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurodegenerative Diseases, Synaptosomal-Associated Protein 25, Neurogranin, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13195-022-01002-x
- The paper
- Kivisäkk, P., Carlyle, B. C., Sweeney, T., Quinn, J. P., Ramirez, C. E., Trombetta, B. A., Mendes, M., Brock, M., Rubel, C., Czerkowicz, J., Graham, D., & Arnold, S. E. (2022). Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-022-01002-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.